Kerala Ayurveda Ltd. (KERALAYUR): Kerala Ayurveda Share Price Rises 9.99% as Stock Clears Micro Cap Threshold

Kerala Ayurveda Share Price Today stood at Rs 176.65, up 9.99%, taking market capitalisation to Rs 208.7 crore and placing the BSE stock among the session’s notable micro cap gainers.

Kerala Ayurveda Share Price moved to Rs 176.65 on 17 August 2026, up Rs 16.05 or 9.99% from the previous close of Rs 160.60, lifting the company’s market capitalisation to Rs 208.7 crore.

The verified data confirms the price event clearly: the stock opened at Rs 176.65, traded at a day high of Rs 176.65 and a day low of Rs 176.65, and recorded turnover of Rs 0.16 crore on BSE volume of 8,995 shares. In other words, Kerala Ayurveda Share Price Today reflected an immediate step-up from the prior close rather than a broad intraday range.

Why is it trending? The supplied data confirms the magnitude of the move and its market-cap classification, but it does not establish a company-specific catalyst behind today’s rise. That distinction matters in Kerala Ayurveda Stock News because price action can be confirmed even when the reason is not identified by the supplied dataset.

Important metrics for investors to monitor next include the stock’s valuation multiples, profitability ratios and how they compare with the Healthcare sector’s Pharmaceuticals & Drugs benchmark. Univest notes that while the share price gain is significant for the day, the deeper reading comes from combining price action with fundamental analysis, sector context and peer comparison.

Kerala Ayurveda Ltd. (KERALAYUR) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 176.65
Previous Close	Rs 160.6
Today's Change	+Rs 16.05 (+9.99%)
Day Open	Rs 176.65
Day High	Rs 176.65
Day Low	Rs 176.65
Current Volume (BSE)	8,995
BSE Traded Volume	8,995
Combined NSE + BSE Volume	8,995
Turnover	Rs 0.16 crore
Market Capitalisation	Rs 208.7 crore
Market Cap Category	Micro Cap

Kerala Ayurveda Ltd. (KERALAYUR) traded at Rs 176.65. versus the previous close of Rs 160.6, a rise of 9.99%. The stock opened at Rs 176.65, reached Rs 176.65, touched Rs 176.65. Reported volume was 8,995.

Kerala Ayurveda Ltd. (KERALAYUR) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 208.7 crore
P/E Ratio	-8.66x
P/B Ratio	-10.34x
ROE	-183.03%
ROCE	-0.45%
EPS	Rs -20.41
Dividend Yield	0%

Kerala Ayurveda Ltd. was valued at a P/E ratio of -8.66x, a P/B ratio of -10.34x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -183.03% and ROCE of -0.45%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -20.41, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Kerala Ayurveda Share Price is getting attention because of today’s move, but the supplied fundamentals present a more difficult backdrop. The company’s market capitalisation stands at Rs 208.7 crore, which places it above the same-industry median market cap of Rs 137.8 crore but below the same-industry average of Rs 481.52 crore. That shows Kerala Ayurveda is not among the smallest names in the Pharmaceuticals & Drugs set, yet it remains firmly in the micro cap bracket.

On valuation, the company’s P/E ratio is -8.66 and its P/B ratio is -10.34. Negative valuation multiples usually reflect underlying losses or negative net worth dynamics in the reported numbers, and that is consistent with the profitability figures supplied here. Kerala Ayurveda Share Price therefore cannot be read through conventional “cheap versus expensive” lenses in the same way as profitable peers with positive earnings and positive book value multiples.

Profitability metrics are weak in the supplied snapshot. Return on equity is -183.03%, while return on capital employed is -0.45%. In simple terms, ROE measures the return generated on shareholder equity and ROCE measures returns on capital employed, and both figures here are below zero. That challenges the idea that the current Kerala Ayurveda Share Price Rise is being explained by strong reported profitability.

EPS is -20.41, meaning earnings attributable to each share are negative on the supplied basis. Dividend yield is 0, which indicates there is no current historical payout yield reflected against the present market price. These two figures matter because they shape how investors frame Kerala Ayurveda Fundamental Analysis: the stock is being discussed today because of price action, not because the snapshot shows earnings strength or income support.

For readers following Kerala Ayurveda Stock News, the main takeaway is balanced. Today’s price rise is real and meaningful for a micro cap stock, but the current fundamental profile remains weak on earnings, return ratios and valuation quality. That is why Univest views the next layer of analysis through sector benchmarks and peer comparison rather than price movement alone.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	-8.66x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	-10.34x
Benchmark Median P/B	1.77x
Company ROE	-183.03%
Benchmark Median ROE	9.91%
Company ROCE	-0.45%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 208.7 crore
Benchmark Median Market Cap	Rs 137.8 crore

Kerala Ayurveda Ltd. (KERALAYUR) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -8.66x, which is below the benchmark median of 26.47x, a difference of -132.72%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Kerala Ayurveda Ltd. (KERALAYUR) has a ROE of -183.03%, which is below the benchmark median of 9.91%, a difference of -1,946.92%. Kerala Ayurveda Ltd. (KERALAYUR) has a ROCE of -0.45%, which is below the benchmark median of 12.79%, a difference of -103.52%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Kerala Ayurveda operates in Healthcare, within the Pharmaceuticals & Drugs industry, and the supplied benchmark offers a strong comparison base. Against 139 same-industry companies, the stock’s valuation and return ratios sit well below the median on profitability, even as its market capitalisation is above the industry median.

The sectorSnapshot covers the same industry and includes 139 companies for market-cap comparison, 105 companies for P/E comparison, and 138 companies each for P/B, ROE and ROCE comparison. Kerala Ayurveda Share Price sits in a company with a P/E of -8.66, versus an industry median P/E of 26.47 and an average of 40.28. The same industry range runs from 2.98 to 361.02. Since the company’s P/E is negative, it stands outside the positive earnings profile implied by most of the benchmark set.

The P/B ratio also stands out. Kerala Ayurveda’s company P/B is -10.34, while the same-industry median is 1.77 and the average is 2.33, with a range from -21.33 to 27.19. On profitability, company ROE is -183.03%, far below the benchmark median of 9.91% and average of 7.3%. Company ROCE is -0.45%, also below the benchmark median of 12.79% and average of 14.83%.

Where the company looks less out of place is scale. Its market capitalisation of Rs 208.7 crore is higher than the industry median of Rs 137.8 crore, though lower than the average of Rs 481.52 crore. The industry’s market-cap range spans from Rs 2.19 crore to Rs 2,985.15 crore. In sector analysis terms, that means Kerala Ayurveda is not unusually small within the peer set, but its current profitability and valuation metrics lag the broader Pharmaceuticals & Drugs benchmark.

For investors tracking Kerala Ayurveda Share Price Today, Univest would frame the sector picture this way: the stock’s move is notable in Market News, but the benchmark comparison does not yet show stronger-than-industry fundamentals. That makes peer context especially important.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	184.72	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15

Kerala Ayurveda Ltd. (KERALAYUR) has a P/E ratio of -8.66x compared with the displayed peer median of 58.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -183.03% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at -0.45% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Kerala Ayurveda Ltd. (KERALAYUR) has a market capitalisation of Rs 208.7 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Kerala Ayurveda Share Price looks very different from the supplied peer set when compared on scale, valuation and returns. Most of the listed peers in the benchmark snapshot are substantially larger by market capitalisation and show stronger return ratios, even when some have mixed valuation readings.

At Rs 208.7 crore in market capitalisation, Kerala Ayurveda is much smaller than Dishman Carbogen Amcis at Rs 2,985.15 crore, Beta Drugs at Rs 2,827.67 crore, Hikal at Rs 2,686.72 crore, Ind-Swift Laboratories at Rs 2,645.37 crore and Fredun Pharmaceuticals at Rs 2,559.68 crore. NGL Fine-Chem, Venus Remedies, Panacea Biotec, Sai Parenteral’s and Solara Active Pharma Sciences are also all far larger on the supplied figures.

On valuation, Kerala Ayurveda’s P/E of -8.66 contrasts with positive P/E readings such as Venus Remedies at 20.56, NGL Fine-Chem at 37.4, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Beta Drugs at 68.16, Sai Parenteral’s at 171 and Dishman Carbogen Amcis at 184.72. Some peers do not have a supplied P/E in this dataset, but where numbers are available, Kerala Ayurveda’s negative multiple marks it out as an earnings-outlier.

The same pattern appears in profitability. Kerala Ayurveda’s ROE of -183.03% is materially weaker than Beta Drugs at 18.65%, Hikal at 15.22%, Fredun Pharmaceuticals at 11.42%, Venus Remedies at 9.85% and NGL Fine-Chem at 27.9%. Even Dishman Carbogen Amcis at -2.89% and Ind-Swift Laboratories at -0.78% are less negative on ROE. On ROCE, Kerala Ayurveda at -0.45% trails Beta Drugs at 22.17%, Hikal at 16.15%, Fredun Pharmaceuticals at 13.15%, Venus Remedies at 7.89% and NGL Fine-Chem at 33.91%.

P/B comparison is also telling. Kerala Ayurveda’s P/B is -10.34, while peers such as Dishman Carbogen Amcis are at 0.45, Ind-Swift Laboratories at 1.77, Hikal at 2.26, Panacea Biotec at 2.9, Sai Parenteral’s at 3.13, Venus Remedies at 3.48, NGL Fine-Chem at 6.15, Beta Drugs at 6.74 and Fredun Pharmaceuticals at 8.73. In short, Kerala Ayurveda Share Price is rising today, but relative numbers place the company in the weaker end of this peer set on profitability and conventional valuation quality.

Why Investors Are Watching Kerala Ayurveda

Kerala Ayurveda Share Price is on investor radar because the stock delivered a clear same-day gain that was large enough to qualify in its market-cap bucket. In Stocks in News and Top Gainers Today screens, such moves attract attention quickly, especially when they happen at the open and immediately reset the quoted trading range.

• Verified price action: the stock rose 9.99% to Rs 176.65 from Rs 160.60, a gain of Rs 16.05.
• Category relevance:< 99%.
• Trading snapshot: open, high and low were all Rs 176.65 in the supplied capture, with BSE volume of 8,995 shares and turnover of Rs 0.16 crore.
• Fundamental context: P/E is -8.66, P/B is -10.34, ROE is -183.03%, ROCE is -0.45%, EPS is -20.41 and dividend yield is 0.
• Sector positioning: the company’s P/E, ROE and ROCE are below the Pharmaceuticals & Drugs benchmark medians.

What should investors monitor next? The practical checklist includes whether Kerala Ayurveda Share Price holds above today’s step-up level, whether turnover expands from the current Rs 0.16 crore, and whether later Kerala Ayurveda Share News is matched by improving earnings or return ratios. Univest sees the current move as confirmed market action, while the supplied dataset keeps the fundamental debate open rather than settled.

About Kerala Ayurveda

Kerala Ayurveda Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry in the supplied market dataset. That places the company in a broad listed universe where investors often compare businesses through valuation, profitability and market-cap filters. In Kerala Ayurveda Stock Analysis terms, the company is currently being tracked more through market behaviour and peer positioning than through a detailed operating description in the supplied data.

What can be said factually is that Kerala Ayurveda is listed under the symbol KERALAYUR and is being assessed against a same-industry benchmark of 139 companies. Its market capitalisation of Rs 208.7 crore puts it above the industry median of Rs 137.8 crore, but still far below many larger listed Pharmaceuticals & Drugs names in the peer set. That makes Kerala Ayurveda a smaller listed healthcare player within its industry context.

Because the supplied company overview fields do not include product lines, revenue mix or business segments, the clearest company context for readers comes from where it sits in the market structure: a micro cap Healthcare stock, listed on BSE in the current trading snapshot, and compared against other pharmaceuticals and drug companies on P/E, P/B, ROE and ROCE. For investors reading Kerala Ayurveda Latest News, that industry placement is central to understanding how today’s price rise should be interpreted.

Track Kerala Ayurveda Share Price on Univest

Use Kerala Ayurveda Ltd. (KERALAYUR) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Kerala Ayurveda Share Price can use Univest to track live market moves, valuation ratios and broader stock analysis in one place. Kerala Ayurveda Share Price Today, 52-week levels, market capitalisation, price action, shareholding pattern when available, and key financial metrics can all help users compare one trading session with the longer-term financial picture.

Univest also helps readers place Kerala Ayurveda Share Price Update items inside a wider context that includes peer comparison, sector benchmarks and market insights. For users looking beyond a single headline move in the Indian Stock Market, that combination can be useful when reviewing Kerala Ayurveda Stock News, Kerala Ayurveda BSE activity and broader Healthcare market movers.

Frequently Asked Questions

Why is Kerala Ayurveda Share Price rising today?

Ans. Kerala Ayurveda Share Price rose 9.99% to Rs 176.65 from the previous close of Rs 160.60. The supplied data confirms the price event and its Micro Cap threshold qualification, but it does not establish a company-specific catalyst.

What is Kerala Ayurveda Share Price Today?

Ans. Kerala Ayurveda Share Price Today is Rs 176.65 as per the supplied market snapshot dated 17 August 2026 at 9:17:26 AM IST. The stock was up Rs 16.05, or 9.99%, versus the previous close.

How much did Kerala Ayurveda stock gain in today’s session?

Ans. Kerala Ayurveda stock gained Rs 16.05 in absolute terms and 9.99% in percentage terms. The move took the stock from a previous close of Rs 160.60 to a current price of Rs 176.65 in today’s trading snapshot.

<

Ans. Yes. 99%. That is why it appears in a price rise threshold-based gainer screen.

What does today’s trading pattern show for Kerala Ayurveda?

Ans. The supplied snapshot shows Kerala Ayurveda opened at Rs 176.65 and the day’s high and low were also Rs 176.65. That means the captured move appeared as an immediate step-up from the prior close rather than a wide intraday range.

How much volume was traded in Kerala Ayurveda today?

Ans. Kerala Ayurveda recorded volume of 8,995 shares on BSE in the supplied snapshot, with turnover of Rs 0.16 crore. That shows a meaningful percentage gain for the day, though rupee turnover remained modest in absolute terms.

What is Kerala Ayurveda’s market capitalisation?

Ans. Kerala Ayurveda’s market capitalisation is Rs 208.7 crore. Within the supplied Pharmaceuticals & Drugs benchmark, that is above the median market cap of Rs 137.8 crore but below the average of Rs 481.52 crore.

What do Kerala Ayurveda’s valuation ratios show?

Ans. Kerala Ayurveda has a P/E ratio of -8.66 and a P/B ratio of -10.34 in the supplied data. These negative multiples sit well below the industry median P/E of 26.47 and median P/B of 1.77.

How profitable is Kerala Ayurveda based on the supplied figures?

Ans. The supplied profitability metrics are weak: ROE is -183.03%, ROCE is -0.45% and EPS is -20.41. These numbers indicate the company’s current financial snapshot is not showing positive earnings or strong return generation.

How does Kerala Ayurveda compare with peers in Pharmaceuticals & Drugs?

Ans. Kerala Ayurveda is much smaller than peers like Dishman Carbogen Amcis, Beta Drugs and Hikal, and its ROE and ROCE are weaker than many listed comparables. Its negative P/E also contrasts with several peers carrying positive earnings multiples.